List of Excipients in Branded Drug DOXEPIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	0378-4810	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	0378-4810	FD&C BLUE NO. 1
Mylan Pharmaceuticals Inc	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	0378-4810	MAGNESIUM STEARATE

Generic Drugs Containing DOXEPIN

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	doxepin	0228-3315	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Actavis Pharma Inc	doxepin	0228-3315	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	doxepin	0228-3315	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in DOXEPIN?

# Of NDCs	Excipient
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
14	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM

Doxepin Excipient Strategy, Formulation Patents, Generic Competition, and Commercial Opportunities

Last updated: November 5, 2026

Doxepin is a mature tricyclic compound with two active pharmaceutical markets: high-dose antidepressant and antipruritic products, and low-dose insomnia products marketed primarily as Silenor. The active ingredient has limited composition-of-matter protection remaining, so commercial value is concentrated in differentiated delivery systems, excipient performance, regulatory positioning, manufacturing efficiency, and lifecycle management.

The strongest excipient opportunities are low-dose content uniformity, taste masking, alcohol-free liquid delivery, modified release, topical tolerability, and products designed for patients who cannot use conventional tablets or capsules.

What is doxepin and which dosage forms are commercially relevant?

Doxepin hydrochloride is a tricyclic antidepressant with potent H1 histamine-receptor antagonism. FDA-approved products use doxepin in different dose ranges and delivery systems:

Product category	Typical strength	Primary use	Commercial status
Doxepin capsules	10, 25, 50, 75, 100, 150 mg	Depression and anxiety	Generic market
Doxepin tablets	Varies by manufacturer	Depression and anxiety	Generic market
Silenor tablets	3 and 6 mg	Insomnia characterized by difficulty with sleep maintenance	Brand and generic competition
Doxepin oral concentrate	10 mg/mL in some markets	Depression and anxiety	Limited, formulation-specific market
Doxepin cream	5%	Atopic dermatitis and lichen simplex chronicus pruritus	Generic topical market

Silenor is a low-dose formulation distinct from conventional antidepressant dosing. The FDA approved Silenor 3 mg and 6 mg tablets in 2010 for sleep-maintenance insomnia. Doxepin capsules and oral concentrate are generally dosed at materially higher levels for psychiatric indications. FDA labeling identifies somnolence and sedation as clinically relevant safety considerations across products, while low-dose insomnia products target hypnotic use at substantially lower exposure than antidepressant therapy (FDA, 2010a; FDA, 2010b).

What excipients are used in doxepin tablets and capsules?

Doxepin solid oral products commonly use conventional excipient systems based on lactose, microcrystalline cellulose, starch, colloidal silicon dioxide, magnesium stearate, gelatin, and film-coating materials.

Common excipient functions

Excipient class	Typical materials	Function in doxepin products
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass, compressibility, dose uniformity
Disintegrant	Corn starch, pregelatinized starch, croscarmellose sodium	Tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Powder flow and blend uniformity
Lubricant	Magnesium stearate	Ejection and manufacturing control
Capsule shell	Gelatin, titanium dioxide, colorants	Dosage-form enclosure and identification
Film coating	Hypromellose, titanium dioxide, triacetin, colorants	Appearance, protection, swallowability
Liquid vehicle	Purified water, glycerin, alcohol or cosolvents	Solubilization and dose delivery
Preservative	Methylparaben, propylparaben or alternatives	Microbial control in multidose liquids
Topical vehicle	Propylene glycol, alcohols, water, surfactants	Solubilization and skin delivery

Silenor labeling identifies lactose monohydrate, microcrystalline cellulose, pregelatinized starch, magnesium stearate, colloidal silicon dioxide, and coating components including hypromellose, titanium dioxide, triacetin, and colorants (FDA, 2010a). Exact excipient composition varies by manufacturer and strength.

The existing excipient platform is technically adequate but commercially undifferentiated. A new product must create measurable value through dose flexibility, tolerability, stability, administration, or regulatory exclusivity.

Which excipient strategies offer the strongest commercial opportunities for doxepin?

1. Low-dose content uniformity and blend segregation control

The 3 mg and 6 mg insomnia strengths create a difficult low-dose manufacturing problem. Doxepin hydrochloride represents a small fraction of total tablet weight, increasing the risk of blend segregation and unit-to-unit variability.

Commercially relevant strategies include:

• Ordered mixing using microcrystalline cellulose or spray-dried lactose.
• Carrier-based dry granulation.
• Wet granulation with controlled binder addition.
• Co-processed excipients for improved flow.
• In-process near-infrared monitoring.
• Particle-size engineering of doxepin hydrochloride.
• Direct compression platforms with narrow excipient particle-size distributions.

A formulation that improves content uniformity without increasing tablet size could support a differentiated 3 mg or 6 mg product. The strongest intellectual-property position would generally cover the manufacturing process, particle-size range, blend composition, or dissolution profile rather than the use of a conventional excipient alone.

2. Alcohol-free and sugar-free oral liquids

Liquid doxepin products can address geriatric patients, patients with dysphagia, and flexible dose titration. A conventional liquid may rely on alcohol or other cosolvents to maintain solubility. An alcohol-free formulation could improve suitability for pediatric, geriatric, institutional, and chronic-use settings.

Potential excipient systems include:

• Glycerin and propylene glycol cosolvent blends.
• Polyethylene glycol systems.
• Cyclodextrin complexation.
• pH adjustment with citrate or phosphate buffers.
• Non-sugar sweeteners such as sucralose or acesulfame potassium.
• Flavor systems compatible with doxepin’s bitter profile.
• Preservative systems supported by antimicrobial effectiveness testing.

The main development risks are precipitation after dilution, preservative incompatibility, taste, adsorption to dosing devices, and stability during repeated opening. A ready-to-use, alcohol-free liquid with a calibrated oral syringe could be positioned as a differentiated 505(b)(2) product if it provides a clinically or administratively meaningful advantage.

3. Taste masking and orally disintegrating tablets

Doxepin has a bitter pharmaceutical taste. An orally disintegrating tablet could improve administration for patients who cannot swallow conventional tablets, but rapid dissolution can increase taste exposure.

Potential approaches include:

• Ion-exchange resin complexes.
• Polymer coatings on doxepin particles.
• Lipid or wax microparticles.
• Cyclodextrin complexes.
• Functional coating polymers.
• Effervescent or saliva-triggered matrix systems.
• Multiparticulate orally disintegrating systems.

The target product should release doxepin after the dosage form passes the oral cavity, while maintaining rapid gastrointestinal availability. A taste-masked ODT would have commercial value if it avoids a large tablet, preserves low-dose uniformity, and demonstrates bioequivalence or a defensible 505(b)(2) pathway.

4. Modified-release delivery

Modified-release doxepin is a potential lifecycle strategy, although its commercial rationale must be linked to a specific clinical problem. Relevant objectives could include:

• Delayed release to target sleep maintenance later in the night.
• Reduced early-evening sedation.
• Extended exposure from a single low dose.
• Lower peak concentration.
• Reduced next-day impairment.
• Once-daily psychiatric dosing with improved tolerability.

Hydrophilic matrices, multiparticulates, coated pellets, osmotic systems, and gastroretentive systems are possible platforms. The technical challenge is aligning release kinetics with doxepin’s pharmacology and safety profile. A modified-release product that increases total exposure or prolongs sedation without a clear benefit would face weak commercial differentiation.

5. Topical excipient optimization

Doxepin 5% cream is used for pruritus associated with atopic dermatitis and lichen simplex chronicus. Topical formulations create different excipient opportunities from oral products.

Relevant development targets include:

• Lower systemic absorption.
• Reduced stinging and burning.
• Lower skin irritation.
• Improved spreadability.
• Reduced greasiness.
• Better wash-off resistance.
• Improved compatibility with damaged skin.
• Preservative systems suitable for chronic or intermittent use.

Topical doxepin can be formulated as a cream, gel, emulsion, foam, spray, or lotion. A gel or foam could improve patient acceptability, but the product would need to preserve local efficacy while limiting systemic exposure. The FDA label warns about drowsiness and systemic absorption with topical doxepin, particularly when large areas are treated or occlusion is used (FDA, 2010c).

What patents protect doxepin products and formulations?

Doxepin’s original composition-of-matter protection is long expired. Conventional doxepin capsules, tablets, and cream products are exposed to generic competition. The principal remaining protection opportunities involve product-specific formulation and use claims.

Protection category	Relevance to doxepin	Current commercial significance
Composition of matter	Doxepin molecule and hydrochloride salt	Expired for practical commercial purposes
Conventional oral dosage forms	Capsules and immediate-release tablets	Weak protection; generic competition
Low-dose insomnia use	3 mg and 6 mg sleep-maintenance dosing	Historical brand differentiation; exclusivity largely expired
Modified release	Release profile, dose timing, or pharmacokinetic exposure	Potential lifecycle opportunity
Taste masking	Coated particles, resin complexes, ODTs	Potential formulation and process claims
Liquid formulation	Solvent, buffer, preservative, flavor, and stability system	Potential 505(b)(2) opportunity
Topical delivery	Vehicle, absorption control, irritation reduction	Product-specific opportunity
Manufacturing process	Particle size, blending, granulation, coating, and controls	Useful where composition claims are narrow
Method of treatment	Insomnia, pruritus, psychiatric disorders, or subpopulations	Vulnerable to prior art and obviousness challenges

Silenor received FDA approval in 2010, and its historical regulatory exclusivity period has expired. The product’s commercial protection therefore depends primarily on any surviving patent claims, approved-label distinctions, trademarks, supply arrangements, and prescriber familiarity rather than new chemical exclusivity (FDA, 2010a; FDA, 2024a).

Patent strength is highest where a formulation claim combines several measurable limitations, such as a defined particle-size range, excipient ratio, dissolution profile, impurity limit, and pharmacokinetic result. A claim covering only lactose, magnesium stearate, or a standard coating polymer is generally easier to design around and less likely to create durable market exclusivity.

When does doxepin lose exclusivity and what is the Orange Book status?

Doxepin has already lost the exclusivity that protects a new chemical entity. Generic doxepin products are approved under abbreviated new drug applications, and multiple manufacturers compete in conventional oral dosage forms.

The FDA Orange Book distinguishes between approved products and listed patents. For a specific product, the relevant analysis requires review of:

• The current Reference Listed Drug.
• Listed patents and pediatric-exclusivity information.
• Paragraph IV certifications.
• Approved strengths and dosage forms.
• Labeling differences.
• Therapeutic-equivalence ratings.

The practical market position is clear: conventional doxepin capsules and tablets are genericized, while low-dose insomnia formulations have limited remaining protection. No biosimilar pathway applies because doxepin is a small-molecule drug, not a biologic. The relevant competitive mechanisms are ANDAs, 505(b)(2) applications, formulation patents, and method-of-use patents.

Which companies are challenging doxepin products?

The conventional doxepin market is challenged by generic manufacturers rather than biosimilar developers. Generic competition includes companies that manufacture or distribute doxepin capsules, tablets, oral concentrate, and topical cream depending on the product and market.

Commercial competitors can be divided into four groups:

1. Manufacturers of low-cost immediate-release capsules and tablets.
2. Generic suppliers of doxepin cream.
3. Brand or authorized-generic suppliers associated with low-dose insomnia products.
4. Specialty developers pursuing liquid, ODT, modified-release, or topical reformulations.

Paragraph IV risk is most relevant to any newly listed patent covering a reformulated doxepin product. For legacy immediate-release products, competitive risk is primarily price erosion and supply substitution, not a new patent challenge. Litigation exposure depends on the patent portfolio of the particular branded or reformulated product and should be assessed against current FDA Orange Book listings and federal court dockets.

What FDA regulatory pathways apply to new doxepin formulations?

Abbreviated New Drug Application

An ANDA is appropriate for a product that is therapeutically equivalent to the relevant reference product. The applicant must meet requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and applicable inactive-ingredient controls.

This is the lowest-risk path for a conventional generic capsule, tablet, or cream, but it provides limited differentiation and typically results in price competition.

505(b)(2) application

A 505(b)(2) application may be appropriate for:

• A new liquid vehicle.
• An orally disintegrating tablet.
• A modified-release tablet.
• A new topical dosage form.
• A different dose or administration method.
• A formulation with a new clinical-use rationale.

The product sponsor may rely partly on FDA findings for previously approved doxepin products while submitting new formulation, pharmacokinetic, safety, or efficacy data. Patent certification and labeling requirements still apply.

NDA pathway

A full NDA is less likely to be commercially attractive for a simple reformulation unless the product has a materially new therapeutic profile, a new indication, or a substantial clinical advantage.

How strong is the doxepin patent estate?

The legacy patent estate is weak for conventional products and potentially moderate for engineered reformulations.

Asset type	Patent strength	Main weakness
Doxepin molecule	Very low	Long-expired originator protection
Standard capsule	Very low	Established generic technology
Standard tablet	Very low	Easy substitution and prior art
Low-dose insomnia product	Low to moderate	Historical exclusivity has expired
ODT with taste masking	Moderate	Extensive formulation prior art
Alcohol-free liquid	Moderate	Need to prove non-obvious stability and performance
Modified release	Moderate	Clinical benefit must justify complexity
Topical absorption control	Moderate	Safety and local-efficacy data required
Manufacturing process	Moderate	Claims may be narrow and design-around risk is high

The most defensible portfolio would combine composition claims, process claims, dosage-form claims, and method-of-use claims. Regulatory exclusivity, if available, should be treated as a supplement to patents rather than the principal commercial barrier.

What commercial opportunities exist for doxepin excipients?

Geriatric and dysphagia-focused products

A small-volume, alcohol-free liquid or taste-masked ODT could target older adults, long-term-care institutions, and patients with swallowing limitations. Dose-volume control and a standardized dispenser would improve medication administration.

Low-dose insomnia products

The 3 mg and 6 mg strengths create an opportunity for improved tablets with:

• Better content uniformity.
• Smaller tablet size.
• Reduced tablet friability.
• Faster disintegration.
• Lower taste exposure.
• Clear strength differentiation.

A product that supports flexible titration without tablet splitting could also have practical value.

Topical antipruritic products

A non-greasy foam, gel, or lotion could compete on patient experience rather than active-ingredient novelty. A lower-absorption formulation could have a stronger regulatory and commercial rationale if it reduces sedation risk.

Institutional and hospital products

Unit-dose packaging, ready-to-administer liquids, and stable multidose containers may create procurement advantages. These products could compete through workflow efficiency and medication-error reduction rather than retail branding.

Global markets

Excipient selection must account for regional restrictions on colorants, preservatives, alcohol, lactose, titanium dioxide, and animal-derived gelatin. A globally deployable formulation should minimize excipients that trigger country-specific labeling or regulatory review.

How does doxepin compare with competing insomnia drugs?

Drug	Primary mechanism	Formulation opportunity relative to doxepin	Generic pressure
Doxepin	H1 antagonism at low dose	ODT, liquid, modified release, low-dose tablet	High
Zolpidem	GABA-A receptor modulation	Sublingual and modified-release products	High
Eszopiclone	GABA-A receptor modulation	Tablet and taste-management products	High
Ramelteon	Melatonin-receptor agonist	Liquid and modified-release opportunities	Moderate to high
Suvorexant	Orexin-receptor antagonist	Brand and generic lifecycle competition	Increasing
Daridorexant	Orexin-receptor antagonist	New delivery and dose-flexibility strategies	Lower than legacy drugs

Doxepin’s formulation advantage is its very low approved insomnia dose and established generic active ingredient. Its disadvantage is the absence of strong remaining exclusivity and the potential for sedation-related safety concerns. Excipient innovation must therefore improve use, tolerability, or administration.

What litigation and settlement risks affect doxepin?

For legacy doxepin capsules and tablets, litigation risk is generally limited because the products have long been genericized. For a new branded reformulation, risk would arise from:

• Paragraph IV certifications against listed formulation or method patents.
• Obviousness challenges based on known doxepin formulations.
• Design-around products using different polymers, buffers, or coating systems.
• ANDA litigation over low-dose insomnia formulations.
• Patent-term and terminal-disclaimer constraints.
• Settlement agreements that delay generic entry.

Any settlement involving a newly protected doxepin formulation would need review for entry date, authorized-generic provisions, manufacturing rights, and restrictions on reformulation. No biosimilar settlement framework applies.

What generic launch scenarios exist for doxepin?

Scenario 1: Conventional generic substitution

Generic capsules, tablets, and cream continue to compete primarily on price, availability, and wholesaler contracts. Margins remain low unless a supplier has manufacturing cost or supply reliability advantages.

Scenario 2: Low-dose insomnia price erosion

Additional suppliers of 3 mg and 6 mg tablets could reduce brand and authorized-generic pricing. Product differentiation would depend on tablet quality, packaging, payer positioning, and pharmacy availability.

Scenario 3: 505(b)(2) reformulation launch

An alcohol-free liquid, taste-masked ODT, or modified-release product could preserve higher pricing if it obtains a distinct label, formulation claims, or regulatory exclusivity.

Scenario 4: Topical innovation

A lower-irritation or lower-absorption topical product could compete with generic cream and potentially command a specialty-product premium if supported by clinical or pharmacokinetic data.

Key Takeaways

• Doxepin’s original molecule and conventional dosage forms are no longer protected by meaningful new-chemical exclusivity.
• Generic competition is established across capsules, tablets, and topical cream.
• No biosimilar risk applies because doxepin is a small molecule.
• The most attractive excipient opportunities are low-dose uniformity, taste masking, alcohol-free liquids, modified release, and improved topical vehicles.
• Silenor’s historical regulatory exclusivity has expired, leaving formulation patents, trademarks, supply, and labeling differentiation as the principal commercial tools.
• A 505(b)(2) strategy is more commercially defensible than a conventional generic strategy when the formulation provides a clear administration or tolerability advantage.
• Excipient-only claims are usually weak. Stronger portfolios combine excipient composition, manufacturing process, dissolution, pharmacokinetic, and method-of-use claims.
• Commercial success will depend on demonstrated patient or caregiver value, not simply substitution of one standard excipient for another.

FAQs About Doxepin Excipient Strategy

Can lactose-free doxepin tablets be commercially differentiated?

Yes, but lactose removal alone is unlikely to create durable exclusivity. The product would need a broader formulation, labeling, tolerability, or patient-population rationale.

Is an alcohol-free doxepin liquid a viable 505(b)(2) product?

It can be viable if it demonstrates reliable solubility, microbiological control, acceptable taste, dosing accuracy, and a meaningful administration advantage over existing products.

Can doxepin be developed as an orally disintegrating tablet?

Yes. The primary technical issues are bitter taste, low-dose content uniformity, moisture sensitivity, tablet strength, and rapid but controlled dissolution.

Does doxepin have biosimilar competition?

No. Doxepin is a small-molecule drug. Competition occurs through ANDAs, 505(b)(2) applications, formulation patents, and generic manufacturing.

What is the highest-value excipient opportunity for doxepin?

A low-dose, taste-masked, rapidly disintegrating tablet or alcohol-free liquid has the clearest opportunity because it addresses dose uniformity, administration, and patient acceptability while supporting a potential 505(b)(2) strategy.

References

1. U.S. Food and Drug Administration. (2010a). Silenor (doxepin hydrochloride) tablets, prescribing information.
2. U.S. Food and Drug Administration. (2010b). Doxepin hydrochloride capsules, prescribing information.
3. U.S. Food and Drug Administration. (2010c). Doxepin hydrochloride cream, 5%, prescribing information.
4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database.
6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
7. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.